Confo Therapeutics, a leading company in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), has appointed Stephen Dowd as chief business officer, effective 12 September. Mr Dowd has 25 years of experience in biotechnology and pharmaceutical companies and will work with Confo’s executive team to advance the company’s product pipeline and expand the use of its technology platform across multiple therapeutic areas. Mr Dowd joined Confo from Rallybio, a clinical-stage Nasdaq-listed rare disease company where he was head of business development, Europe.
Previously, he held senior positions in business development at Kymab, a clinical-stage antibody-focused biotech which was sold to Sanofi in 2021, and at SNIPR Biome, a CRISPR microbiome therapeutics company. Mr Dowd has a PhD from the University of Dundee for his work at the Imperial Cancer Research Fund (now Cancer Research UK) and an MBA from the University of Cambridge Judge Business School, both UK.
Copyright 2023 Evernow Publishing Ltd